FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912349624> ?p ?o ?g. }

• W2912349624 endingPage "664" @default.
• W2912349624 startingPage "664" @default.
• W2912349624 abstract "Hypofractionated radiotherapy (HRT) would be more convenient for men with low-risk prostate cancer and cost less than conventional radiotherapy (CRT) as long as HRT is noninferior to CRT in terms of survival and quality of life (QOL) is not found to be worse.To assess differences in QOL between men with low-risk prostate cancer who are treated with HRT vs CRT.In this phase 3 randomized clinical trial, men with low-risk prostate cancer were enrolled from sites within the National Cancer Institute's National Clinical Trials Network in the United States, Canada, and Switzerland.Random assignment to CRT (73.8 Gy in 41 fractions over 8.2 weeks) or to HRT (70 Gy in 28 fractions over 5.6 weeks).Quality of life was assessed using the Expanded Prostate Index Composite questionnaire measuring bowel, urinary, sexual, and hormonal domains; the 25-item Hopkins Symptom Checklist measuring anxiety and depression; and the EuroQol-5 Dimension questionnaire measuring global QOL. All data were collected at baseline and 6, 12, 24, and 60 months. Change scores were compared between treatment arms using the Wilcoxon signed rank test. A significance level of .0125 to adjust for multiple comparisons was used for an overall 2-sided type 1 error of .05. Clinical significance was determined for the Expanded Prostate Index Composite change scores by an effect size of 0.5.Of 1092 patients analyzable for the primary end point, 962 (mean [SD] age, 66.6 [7.4] years) consented to the QOL component. No statistically significant differences with regard to baseline characteristics nor any of the QOL baseline domains were measured between arms. There were no differences in change score between arms with respect to any of the Expanded Prostate Index Composite questionnaire domain scores except at 12 months when the HRT arm had a larger decline than the CRT arm in the bowel domain (mean score, -7.5 vs -3.7, respectively; P<.001), but it did not reach clinical significance (effect size = 0.29). There were no differences between arms at any time point for the Hopkins Symptom Checklist nor EuroQol-5 Dimension questionnaire.Treatment with HRT is noninferior to CRT in men with low-risk prostate cancer in terms of disease-free survival and, as shown in the present study, in prostate cancer-specific (eg, bowel, bladder, sexual) and general QOL, as well as in anxiety and depression. This study provides evidence to affirm that HRT is a practice standard for men with low-risk prostate cancer.ClinicalTrials.gov identifier: NCT00331773." @default.
• W2912349624 created "2019-02-21" @default.
• W2912349624 creator A5004249940 @default.
• W2912349624 creator A5004625690 @default.
• W2912349624 creator A5005691073 @default.
• W2912349624 creator A5006174923 @default.
• W2912349624 creator A5015096941 @default.
• W2912349624 creator A5015475982 @default.
• W2912349624 creator A5016976503 @default.
• W2912349624 creator A5019525982 @default.
• W2912349624 creator A5027101830 @default.
• W2912349624 creator A5036433314 @default.
• W2912349624 creator A5038819739 @default.
• W2912349624 creator A5042766411 @default.
• W2912349624 creator A5045162411 @default.
• W2912349624 creator A5078957606 @default.
• W2912349624 creator A5082271881 @default.
• W2912349624 creator A5090936242 @default.
• W2912349624 creator A5091674984 @default.
• W2912349624 date "2019-05-01" @default.
• W2912349624 modified "2023-09-25" @default.
• W2912349624 title "Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy" @default.
• W2912349624 cites W103296545 @default.
• W2912349624 cites W1965522233 @default.
• W2912349624 cites W1987889140 @default.
• W2912349624 cites W2024756496 @default.
• W2912349624 cites W2028742034 @default.
• W2912349624 cites W2050510185 @default.
• W2912349624 cites W2111723482 @default.
• W2912349624 cites W2136887681 @default.
• W2912349624 cites W2137282952 @default.
• W2912349624 cites W2153836018 @default.
• W2912349624 cites W2161938752 @default.
• W2912349624 cites W2166640793 @default.
• W2912349624 cites W2337386322 @default.
• W2912349624 cites W2465092116 @default.
• W2912349624 cites W2519027667 @default.
• W2912349624 cites W2551386685 @default.
• W2912349624 cites W2593133033 @default.
• W2912349624 cites W2603384438 @default.
• W2912349624 cites W2735523941 @default.
• W2912349624 cites W4214809252 @default.
• W2912349624 cites W4233705502 @default.
• W2912349624 cites W4233717107 @default.
• W2912349624 doi "https://doi.org/10.1001/jamaoncol.2018.6752" @default.
• W2912349624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6459051" @default.
• W2912349624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30763425" @default.
• W2912349624 hasPublicationYear "2019" @default.
• W2912349624 type Work @default.
• W2912349624 sameAs 2912349624 @default.
• W2912349624 citedByCount "37" @default.
• W2912349624 countsByYear W29123496242019 @default.
• W2912349624 countsByYear W29123496242020 @default.
• W2912349624 countsByYear W29123496242021 @default.
• W2912349624 countsByYear W29123496242022 @default.
• W2912349624 countsByYear W29123496242023 @default.
• W2912349624 crossrefType "journal-article" @default.
• W2912349624 hasAuthorship W2912349624A5004249940 @default.
• W2912349624 hasAuthorship W2912349624A5004625690 @default.
• W2912349624 hasAuthorship W2912349624A5005691073 @default.
• W2912349624 hasAuthorship W2912349624A5006174923 @default.
• W2912349624 hasAuthorship W2912349624A5015096941 @default.
• W2912349624 hasAuthorship W2912349624A5015475982 @default.
• W2912349624 hasAuthorship W2912349624A5016976503 @default.
• W2912349624 hasAuthorship W2912349624A5019525982 @default.
• W2912349624 hasAuthorship W2912349624A5027101830 @default.
• W2912349624 hasAuthorship W2912349624A5036433314 @default.
• W2912349624 hasAuthorship W2912349624A5038819739 @default.
• W2912349624 hasAuthorship W2912349624A5042766411 @default.
• W2912349624 hasAuthorship W2912349624A5045162411 @default.
• W2912349624 hasAuthorship W2912349624A5078957606 @default.
• W2912349624 hasAuthorship W2912349624A5082271881 @default.
• W2912349624 hasAuthorship W2912349624A5090936242 @default.
• W2912349624 hasAuthorship W2912349624A5091674984 @default.
• W2912349624 hasBestOaLocation W29123496241 @default.
• W2912349624 hasConcept C121608353 @default.
• W2912349624 hasConcept C126322002 @default.
• W2912349624 hasConcept C159110408 @default.
• W2912349624 hasConcept C203092338 @default.
• W2912349624 hasConcept C2779951463 @default.
• W2912349624 hasConcept C2780192828 @default.
• W2912349624 hasConcept C29456083 @default.
• W2912349624 hasConcept C509974204 @default.
• W2912349624 hasConcept C535046627 @default.
• W2912349624 hasConcept C71924100 @default.
• W2912349624 hasConceptScore W2912349624C121608353 @default.
• W2912349624 hasConceptScore W2912349624C126322002 @default.
• W2912349624 hasConceptScore W2912349624C159110408 @default.
• W2912349624 hasConceptScore W2912349624C203092338 @default.
• W2912349624 hasConceptScore W2912349624C2779951463 @default.
• W2912349624 hasConceptScore W2912349624C2780192828 @default.
• W2912349624 hasConceptScore W2912349624C29456083 @default.
• W2912349624 hasConceptScore W2912349624C509974204 @default.
• W2912349624 hasConceptScore W2912349624C535046627 @default.
• W2912349624 hasConceptScore W2912349624C71924100 @default.
• W2912349624 hasIssue "5" @default.
• W2912349624 hasLocation W29123496241 @default.
• W2912349624 hasLocation W29123496242 @default.

• next